目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 24)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 RESEARCH LIMITATIONS
1.6 STAKEHOLDERS
1.6.1 RECESSION IMPACT: RNA THERAPEUTICS MARKET

2 RESEARCH METHODOLOGY (Page No. - 28)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: RNA THERAPEUTICS MARKET
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 RNA THERAPEUTICS INDUSTRY SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2022
FIGURE 4 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2022
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.3 MARKET GROWTH RATE PROJECTION
FIGURE 6 MARKET (SUPPLY SIDE): CAGR PROJECTIONS
FIGURE 7 GROWTH ANALYSIS OF DEMAND SIDE DRIVERS: MARKET
2.4 MARKET ESTIMATION AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.5 STUDY ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 IMPACT OF ECONOMIC RECESSION ON MARKET
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY (Page No. - 38)
FIGURE 9 RNA THERAPEUTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 10 MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 11 MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 12 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 13 REGIONAL SNAPSHOT: MARKET

4 PREMIUM INSIGHTS (Page No. - 42)
4.1 RNA THERAPEUTICS MARKET OVERVIEW
FIGURE 14 GROWING PARTNERSHIPS AND COLLABORATIONS AMONG KEY PLAYERS TO DRIVE MARKET
4.2 NORTH AMERICA: MARKET SHARE, BY PRODUCT AND COUNTRY (2022)
FIGURE 15 VACCINES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
4.3 NORTH AMERICA: MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 16 INFECTIOUS DISEASES TO DOMINATE NORTH AMERICAN MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 44)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: RNA THERAPEUTICS MARKET
TABLE 4 IMPACT ANALYSIS: RNA THERAPEUTICS INDUSTRY
5.2.1 DRIVERS
5.2.1.1 Increasing partnerships and collaborations between market players and RNA technology manufacturers
5.2.1.2 Increasing number of novel modalities for RNA therapeutics
5.2.1.3 Growing number of emergency use authorizations and approvals for COVID-19 booster vaccines
5.2.2 RESTRAINTS
5.2.2.1 Discontinuation or recalls of RNA therapeutic products
TABLE 5 LIST OF RNA THERAPEUTICS FOR WHICH CLINICAL DEVELOPMENT WAS HALTED
5.2.3 OPPORTUNITIES
5.2.3.1 Higher progress in development of RNA aptamer-based therapeutics
TABLE 6 RNA APTAMERS UNDER CLINICAL DEVELOPMENT
5.2.4 CHALLENGES
5.2.4.1 Rapid degradation by ubiquitous RNases in environment and tissues with strong immunogenicity of exogenous RNA
5.3 TECHNOLOGY ANALYSIS (RNA VACCINE AND THERAPY MANUFACTURING)
5.3.1 PARAMETERS OF MANUFACTURING
5.3.2 CIRCULAR RNA ENGINEERING
5.4 PIPELINE ANALYSIS
FIGURE 18 PIPELINE THERAPIES, BY CATEGORY, 2022
5.4.1 PIPELINE ANALYSIS FOR KEY MARKET PLAYERS (TOP 5)
5.4.1.1 Moderna, Inc.
TABLE 7 PIPELINE CANDIDATES OF MODERNA, INC.
5.4.1.2 Pfizer, Inc.
TABLE 8 PIPELINE CANDIDATES OF PFIZER INC.
5.4.1.3 Alnylam Pharmaceuticals, Inc.
TABLE 9 PIPELINE CANDIDATES OF ALNYLAM PHARMACEUTICALS, INC.
5.4.1.4 Novartis AG
TABLE 10 PIPELINE CANDIDATES OF NOVARTIS AG
5.4.1.5 Ionis Pharmaceuticals, Inc.
TABLE 11 PIPELINE CANDIDATES OF IONIS PHARMACEUTICALS, INC.
5.5 PORTER’S FIVE FORCES ANALYSIS
TABLE 12 PORTER’S FIVE FORCES ANALYSIS: MARKET
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 THREAT OF SUBSTITUTES
5.5.3 BARGAINING POWER OF BUYERS
5.5.4 BARGAINING POWER OF SUPPLIERS
5.5.5 INTENSITY OF COMPETITIVE RIVALRY
5.6 REGULATORY ANALYSIS
TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS OF MARKET: R&D AND MANUFACTURING PHASES ADD MAXIMUM VALUE
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 KEY STAKEHOLDERS AND BUYING CRITERIA
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RNA-BASED THERAPEUTICS
5.9.2 BUYING CRITERIA FOR RNA THERAPEUTIC PRODUCTS/MEDICINES
FIGURE 22 KEY BUYING CRITERIA FOR END USERS
5.10 PRICING ANALYSIS
5.10.1 PRICING ANALYSIS FOR FDA-APPROVED RNA THERAPEUTICS, BY PRODUCT
TABLE 17 AVERAGE SELLING PRICE FOR RNA VACCINES AND DRUGS, BY REGION
5.10.2 PRICING TREND ANALYSIS: RNA VACCINES AND DRUGS
5.11 KEY CONFERENCES AND EVENTS (2023-2024)
TABLE 18 KEY CONFERENCES AND EVENTS IN MARKET (2023-2024)
5.12 ECOSYSTEM MARKET MAP

6 RNA THERAPEUTICS MARKET, BY PRODUCT (Page No. - 65)
6.1 INTRODUCTION
TABLE 19 RNA THERAPEUTICS INDUSTRY, BY PRODUCT, 2021-2028 (USD MILLION)
6.2 VACCINES
6.2.1 INCREASED NUMBER OF APPROVALS AND HIGHER INVESTMENTS FOR COVID-19 BOOSTER VACCINES TO DRIVE MARKET
TABLE 20 MARKET FOR VACCINES, BY REGION, 2021-2028 (USD MILLION)
TABLE 21 NORTH AMERICA: MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 22 EUROPE: MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 23 ASIA PACIFIC: MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
6.3 DRUGS
6.3.1 GROWING FUNDING AND INVESTMENTS IN RNA THERAPEUTICS RESEARCH TO DRIVE MARKET
TABLE 24 MARKET FOR DRUGS, BY REGION, 2021-2028 (USD MILLION)
TABLE 25 NORTH AMERICA: MARKET FOR DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 26 EUROPE: MARKET FOR DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 27 ASIA PACIFIC: MARKET FOR DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)

7 RNA THERAPEUTICS MARKET, BY TYPE (Page No. - 70)
7.1 INTRODUCTION
TABLE 28 RNA THERAPEUTICS INDUSTRY, BY TYPE, 2021-2028 (USD MILLION)
7.2 MRNA THERAPEUTICS
7.2.1 INCREASING INVESTMENTS FOR COVID-19 MRNA VACCINES TO DRIVE MARKET
TABLE 29 MARKET FOR MRNA THERAPEUTICS, BY REGION, 2021-2028 (USD MILLION)
TABLE 30 NORTH AMERICA: MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 31 EUROPE: MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 32 ASIA PACIFIC: MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
7.3 RNA INTERFERENCE (RNAI) THERAPEUTICS
7.3.1 INCREASING NUMBER OF APPROVALS FOR SIRNA THERAPEUTICS BY US FDA TO DRIVE MARKET
TABLE 33 MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2021-2028 (USD MILLION)
TABLE 34 NORTH AMERICA: MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 35 EUROPE: MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 36 ASIA PACIFIC: MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
7.4 ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS
7.4.1 INCREASED NUMBER OF CHEMICAL MODIFICATIONS AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
TABLE 37 MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY REGION, 2021-2028 (USD MILLION)
TABLE 38 NORTH AMERICA: MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 39 EUROPE: MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 40 ASIA PACIFIC: MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
7.5 OTHER THERAPEUTICS

8 RNA THERAPEUTICS MARKET, BY INDICATION (Page No. - 79)
8.1 INTRODUCTION
TABLE 41 RNA THERAPEUTICS INDUSTRY, BY INDICATION, 2021-2028 (USD MILLION)
8.2 INFECTIOUS DISEASES
8.2.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND GROWING INVESTMENTS IN R&D TO DRIVE MARKET
TABLE 42 MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
TABLE 43 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 44 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 45 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
8.3 RARE GENETIC/HEREDITARY DISEASES
8.3.1 TECHNOLOGICAL INNOVATION AND INCREASED DEMAND FOR PERSONALIZED MEDICINES TO DRIVE MARKET
TABLE 46 MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY REGION, 2021-2028 (USD MILLION)
TABLE 47 NORTH AMERICA: MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 48 EUROPE: MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 49 ASIA PACIFIC: MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
8.4 OTHER INDICATIONS
TABLE 50 MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2028 (USD MILLION)
TABLE 51 NORTH AMERICA: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 52 EUROPE: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 53 ASIA PACIFIC: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

9 RNA THERAPEUTICS MARKET, BY END USER (Page No. - 87)
9.1 INTRODUCTION
TABLE 54 RNA THERAPEUTICS INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
9.2 HOSPITALS AND CLINICS
9.2.1 INCREASED PREVALENCE OF CHRONIC DISEASES AND HIGHER EFFICACY OF RNA-BASED THERAPIES TO DRIVE MARKET
TABLE 55 MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021-2028 (USD MILLION)
TABLE 56 NORTH AMERICA: MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 57 EUROPE: MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 58 ASIA PACIFIC: MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
9.3 RESEARCH SETTINGS
9.3.1 HIGHER THERAPEUTIC POTENTIAL OF RNA TECHNOLOGY TO CREATE NEW OPPORTUNITIES IN MEDICAL RESEARCH
TABLE 59 MARKET FOR RESEARCH SETTINGS, BY REGION, 2021-2028 (USD MILLION)
TABLE 60 NORTH AMERICA: MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 61 EUROPE: MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 62 ASIA PACIFIC: MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)

10 RNA THERAPEUTICS MARKET, BY REGION (Page No. - 93)
10.1 INTRODUCTION
TABLE 63 RNA THERAPEUTICS INDUSTRY, BY REGION, 2021-2028 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 23 NORTH AMERICA: RNA THERAPEUTICS MARKET SNAPSHOT
TABLE 64 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 65 NORTH AMERICA: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 66 NORTH AMERICA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 67 NORTH AMERICA: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 68 NORTH AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.2.1 NORTH AMERICA: RECESSION IMPACT
10.2.2 US
10.2.2.1 Growing technological innovation in RNA delivery systems and rising investments in biopharmaceutical research to drive market
TABLE 69 LIST OF RECENT RNA THERAPEUTICS APPROVED BY FDA
TABLE 70 US: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 71 US: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 72 US: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 73 US: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Increasing government initiatives and investments for life science research to drive market
TABLE 74 CANADA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 75 CANADA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 76 CANADA: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 77 CANADA: RNA THERAPEUTICS INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
10.3 EUROPE
TABLE 78 EUROPE: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 79 EUROPE: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 80 EUROPE: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 81 EUROPE: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 82 EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.3.1 EUROPE: RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Rising number of market players and growing public and private funding for research activities to drive market
TABLE 83 GERMANY: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 84 GERMANY: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 85 GERMANY: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 86 GERMANY: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Growing pharmaceutical manufacturing industry and increasing number of clinical trials for oncology to drive market
TABLE 87 FRANCE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 88 FRANCE: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 89 FRANCE: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 90 FRANCE: RNA THERAPEUTICS INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
10.3.4 UK
10.3.4.1 Higher R&D investment by pharmaceutical companies for RNA-based drug discovery to drive market
TABLE 91 UK: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 92 UK: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 93 UK: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 94 UK: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.3.5 REST OF EUROPE
TABLE 95 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 96 REST OF EUROPE: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 97 REST OF EUROPE: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 98 REST OF EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 24 ASIA PACIFIC: RNA THERAPEUTICS MARKET SNAPSHOT
TABLE 99 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 100 ASIA PACIFIC: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 101 ASIA PACIFIC: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 102 ASIA PACIFIC: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 103 ASIA PACIFIC: RNA THERAPEUTICS INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
10.4.1 ASIA PACIFIC: RECESSION IMPACT
10.4.2 JAPAN
10.4.2.1 Increasing geriatric population and rising government initiatives for drug innovation to drive market
TABLE 104 JAPAN: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 105 JAPAN: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 106 JAPAN: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 107 JAPAN: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.4.3 CHINA
10.4.3.1 Low manufacturing costs and increased number of R&D activities to drive market
TABLE 108 CHINA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 109 CHINA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 110 CHINA: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 111 CHINA: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.4.4 SOUTH KOREA
10.4.4.1 Increasing number of government initiatives and growing R&D activities for RNA therapeutics to drive market
TABLE 112 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 113 SOUTH KOREA: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 114 SOUTH KOREA: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 115 SOUTH KOREA: RNA THERAPEUTICS INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
10.4.5 REST OF ASIA PACIFIC
TABLE 116 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 117 REST OF ASIA PACIFIC: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 118 REST OF ASIA PACIFIC: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 119 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.5 REST OF THE WORLD
TABLE 120 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 121 REST OF THE WORLD: MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 122 REST OF THE WORLD: MARKET, BY INDICATION, 2021-2028 (USD MILLION)
TABLE 123 REST OF THE WORLD: RNA THERAPEUTICS INDUSTRY, BY END USER, 2021-2028 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 125)
11.1 OVERVIEW
11.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN RNA THERAPEUTICS MARKET
FIGURE 25 KEY PLAYER STRATEGIES IN RNA THERAPEUTICS INDUSTRY, 2021-2023
11.3 MARKET SHARE ANALYSIS
FIGURE 26 MARKET SHARE ANALYSIS OF TOP 3 PLAYERS IN RNA THERAPEUTICS INDUSTRY, 2022
TABLE 124 DEGREE OF COMPETITION: RNA THERAPEUTICS INDUSTRY
11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP 4 PLAYERS IN RNA THERAPEUTICS INDUSTRY, 2020-2022
11.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 28 COMPANY EVALUATION MATRIX FOR KEY PLAYERS: MARKET, 2022
11.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 DYNAMIC COMPANIES
11.6.4 RESPONSIVE COMPANIES
FIGURE 29 COMPANY EVALUATION MATRIX FOR START-UPS/SMES: MARKET, 2022
11.7 COMPETITIVE BENCHMARKING
TABLE 125 DETAILED LIST OF KEY START-UPS/SMES: MARKET
11.8 COMPETITIVE SCENARIOS AND TRENDS
11.8.1 KEY PRODUCT APPROVALS
TABLE 126 KEY PRODUCT APPROVALS, JANUARY 2021-AUGUST 2023
11.8.2 KEY DEALS
TABLE 127 KEY DEALS, JANUARY 2021-AUGUST 2023
11.8.3 OTHER KEY DEVELOPMENTS
TABLE 128 OTHER KEY DEVELOPMENTS, JANUARY 2021-AUGUST 2023

12 COMPANY PROFILES (Page No. - 137)
(Business overview, Products offered, Recent Developments, MNM view)*
12.1 KEY PLAYERS
12.1.1 MODERNA, INC.
TABLE 129 MODERNA, INC.: COMPANY OVERVIEW
FIGURE 30 MODERNA, INC.: COMPANY SNAPSHOT (2022)
12.1.2 ALNYLAM PHARMACEUTICALS, INC.
TABLE 130 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
FIGURE 31 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)
12.1.3 NOVARTIS AG
TABLE 131 NOVARTIS AG: COMPANY OVERVIEW
FIGURE 32 NOVARTIS AG: COMPANY SNAPSHOT (2022)
12.1.4 IONIS PHARMACEUTICALS, INC.
TABLE 132 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
FIGURE 33 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)
12.1.5 SAREPTA THERAPEUTICS, INC.
TABLE 133 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
FIGURE 34 SAREPTA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2022)
12.1.6 SANOFI
TABLE 134 SANOFI: COMPANY OVERVIEW
FIGURE 35 SANOFI: COMPANY SNAPSHOT (2022)
12.1.7 PFIZER INC.
TABLE 135 PFIZER INC.: COMPANY OVERVIEW
FIGURE 36 PFIZER INC.: COMPANY SNAPSHOT (2022)
12.2 OTHER PLAYERS
12.2.1 ARROWHEAD PHARMACEUTICALS, INC.
12.2.2 BIONTECH SE
12.2.3 ORNA THERAPEUTICS
12.2.4 CRISPR THERAPEUTICS
12.2.5 SILENCE THERAPEUTICS
12.2.6 ASTELLAS PHARMA INC.
12.2.7 CUREVAC SE
12.2.8 SIRNAOMICS
12.2.9 ARCTURUS THERAPEUTICS, INC.
12.2.10 ARBUTUS BIOPHARMA
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

13 APPENDIX (Page No. - 166)
13.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.2 CUSTOMIZATION OPTIONS
13.3 RELATED REPORTS
13.4 AUTHOR DETAILS